Intradigm Licenses RNAi Technology from MIT

Jan 29, 2008

NEW YORK (GenomeWeb News) – Intradigm Corporation has licensed rights to a nucleic acid delivery patent from the Massachusetts Institute of Technology for use in RNAi drug development.

The Palo Alto-based company said the IP it has licensed covers a broad range of biodegradable polymer structures that are used in delivering RNAi-based therapeutics. It added that the license would enable it to pursue applications for its NanoPlex technology across a broader range of therapeutic indications.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

A Winning Diagnostic

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

Science in Africa Unevenly Funded

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

Not Enough Progress?

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

This Week in Science

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Main menu